Your browser doesn't support javascript.
loading
Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients.
Bloom, Jonathan B; Daneshvar, Michael A; Lebastchi, Amir H; Ahdoot, Michael; Gold, Samuel A; Hale, Graham; Mehralivand, Sherif; Sanford, Thomas; Valera, Vladimir; Wood, Bradford J; Choyke, Peter L; Merino, Maria J; Turkbey, Baris; Parnes, Howard L; Pinto, Peter A.
Affiliation
  • Bloom JB; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Daneshvar MA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Lebastchi AH; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Ahdoot M; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Gold SA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Hale G; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Mehralivand S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany.
  • Sanford T; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Valera V; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Wood BJ; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Choyke PL; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Merino MJ; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Turkbey B; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Parnes HL; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Pinto PA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany. Electronic address: pintop@mail.nih.gov.
Urol Oncol ; 39(10): 729.e1-729.e6, 2021 10.
Article in En | MEDLINE | ID: mdl-33736975
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostate / Prostatectomy / Prostatic Neoplasms / Magnetic Resonance Imaging / Image-Guided Biopsy Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Screening_studies Language: En Journal: Urol Oncol Year: 2021 Type: Article Affiliation country: Moldova
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostate / Prostatectomy / Prostatic Neoplasms / Magnetic Resonance Imaging / Image-Guided Biopsy Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Screening_studies Language: En Journal: Urol Oncol Year: 2021 Type: Article Affiliation country: Moldova